DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q8hv2m/investigation) has announced the addition of the "Investigation Report on China Tamsulosin Market, 2010-2019" report to their offering.
Compared with other a1- adrenergic receptor blockers, tamsulosin hydrochloride developed by Yamanouchi enjoys higher selectivity and lower risk of urinary tract infections and therefore is fitter for BPH treatment. Ever since its debut in 1993 in Japan, tamsulosin hydrochloride has been sold in various brands in 64 countries according to Yamanouchi's authorization to Boehringer Ingelheim.
Prostate drug market is highly concentrated in China. Three kinds of prostate drugs - finasteride, tamsulosin and prostat which occupy over 90% of prostate drug market altogether, reported over 10 million sales in sample hospitals in 2005. Tamsulosin develops rapidly after entering China with annual sales less than CNY 50 million in 2005 rising to CNY 201 million in 2014 and CAGR reaching 16.98% during this period. Tamsulosin enjoys a vast market demand in China and products made by Zhejiang Hailisheng Pharmaceutical Co., Ltd, Jiangsu Heng Rui Medicine Co., Ltd, Astellas Pharma Inc, Yamanouchi Pharmaceutical Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd have taken up a large share of the market.
With the aging of the population in China, the incidence of BPH and its number of cases will keep going up. The market size of tamsulosin in China is expected to keep expanding in the next few years.
Key Topics Covered:
1 Related Concepts of Tamsulosin
2 Market Profile of Tamsulosin in China
3 Survey on Sales Status of Tamsulosin in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Tamsulosin in China, 2010-2014
5 Survey on Dosage Forms of Tamsulosin in China, 2010-2014
6 Reference Price of Tamsulosin in Chinese Hospitals in 2014
7 Major Manufacturers of Tamsulosin in Chinese Market, 2010-2014
8 Market Outlook of Tamsulosin in China, 2015-2019
- Zhejiang Hailisheng Pharmaceutical Co., Ltd
- Jiangsu Heng Rui Medicine Co., Ltd
- Kunming Jida Pharmaceutical Co., Ltd
- Yamanouchi Pharmaceutical Co., Ltd
- Astellas Pharma Inc
For more information visit http://www.researchandmarkets.com/research/q8hv2m/investigation